---
title: "RAILY AESMED issued a profit warning, expecting a mid-term loss attributable to shareholders of approximately 8 million yuan, an increase compared to the same period last year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252208252.md"
description: "RAILY AESMED issued a profit warning, expecting a mid-term loss attributable to shareholders of approximately 8 million yuan for the period ending June 30, 2025, an increase compared to the previous year. Revenue is expected to be around 85 million yuan, down from 117 million yuan in the same period last year. The loss is mainly due to a decline in revenue of 32 million yuan caused by intense market competition, as well as increased research and management expenses"
datetime: "2025-08-08T10:38:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252208252.md)
  - [en](https://longbridge.com/en/news/252208252.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252208252.md)
generator: "portal-rs"
---

# RAILY AESMED issued a profit warning, expecting a mid-term loss attributable to shareholders of approximately 8 million yuan, an increase compared to the same period last year

According to the announcement from RAILY AESMED (02135), the board of directors expects the group to achieve approximately RMB 85 million in revenue for the six months ending June 30, 2025 (for the six months ending June 30, 2024: revenue of approximately RMB 117 million); and a loss attributable to the owners of the parent company of approximately RMB 8 million for the six months ending June 30, 2025 (for the six months ending June 30, 2024: loss attributable to the owners of the parent company of approximately RMB 2 million).

The board believes that the loss is mainly due to the following reasons: during the six months ending June 30, 2025 (the reporting period), due to intense market competition, the group's total revenue declined, decreasing by approximately RMB 32 million compared to the total revenue for the six months ending June 30, 2024, resulting in an operating loss of approximately RMB 2 million in the medical beauty services and medical beauty management consulting services segment; during the reporting period, the group's stock option expenses were approximately RMB 1 million; and to accelerate the research and development and production of the group's medical device products, the group increased its investment in the research and development activities of its indirectly non-wholly-owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd. (formerly known as Suzhou Yonglan Biomedical Technology Co., Ltd.). For the six months ending June 30, 2025, the management and research and development expenses of Suzhou Ruichuan were approximately RMB 1 million. These expenses have not yet been recovered from the economic benefits generated during the reporting period

### Related Stocks

- [02930.HK](https://longbridge.com/en/quote/02930.HK.md)
- [02935.HK](https://longbridge.com/en/quote/02935.HK.md)
- [02135.HK](https://longbridge.com/en/quote/02135.HK.md)

## Related News & Research

- [Enterprise Says Partisan Spending Proposals May Complicate Housing Funding Deal](https://longbridge.com/en/news/306339503.md)
- [NRB's (KOSDAQ:475230) Earnings Are Weaker Than They Seem](https://longbridge.com/en/news/306339423.md)
- [INFINITT Healthcare's (KOSDAQ:071200) Shareholders Have More To Worry About Than Lackluster Earnings](https://longbridge.com/en/news/306338723.md)
- [US judge rejects CFTC emergency bid to block New York from policing Kalshi](https://longbridge.com/en/news/306337450.md)
- [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**